Pathophysiological Association between Diabetes Mellitus and Endothelial Dysfunction
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Endothelial dysfunction plays a critical role in atherosclerosis progression, leading to cardiovascular complications. There are significant associations between diabetes mellitus, oxidative stress, and endothelial dysfunction. Oxidative stress is increased by chronic hyperglycemia and acute glucose fluctuations induced by postprandial hyperglycemia in patients with diabetes mellitus. In addition, selective insulin resistance in the phosphoinositide 3-kinase/Akt/endothelial nitric oxide (NO) synthase pathway in endothelial cells is involved in decreased NO production and increased endothelin-1 production from the endothelium, resulting in endothelial dysfunction. In a clinical setting, selecting an appropriate therapeutic intervention that improves or augments endothelial function is important for preventing diabetic vascular complications. Hypoglycemic drugs that reduce glucose fluctuations by decreasing the postprandial rise in blood glucose levels, such as glinides, α-glucosidase inhibitors and dipeptidyl peptidase 4 inhibitors, and hypoglycemic drugs that ameliorate insulin sensitivity, such as thiazolidinediones and metformin, are expected to improve or augment endothelial function in patients with diabetes. Glucagon-like peptide 1 receptor agonists, metformin, and sodium-glucose cotransporter 2 inhibitors may improve endothelial function through multiple mechanisms, some of which are independent of glucose control or insulin signaling. Oral administration of antioxidants is not recommended in patients with diabetes due to the lack of evidence for the efficacy against diabetic complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biochemistry and molecular cell biology of diabetic complications
Brownlee, M. (2001) · Nature · doi:10.1038/414813a · Cited by 9,107
How mitochondria produce reactive oxygen species
Murphy, M. P. (2009) · Biochemical Journal · doi:10.1042/bj20081386 · Cited by 8,207
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Reactive oxygen species (ROS) as pleiotropic physiological signalling agents
Sies, H., & Jones, D. P. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0230-3 · Cited by 5,335 · cited 2×
“In human cells, ROS are produced by various enzymatic sources such as nicotinamide-adenine dinucleotide phosphate (NADPH) oxidases, xanthine dehydrogenase/oxidase, the mitochondrial electron transport chain, uncoupled endothelial NO synthase (eNOS), cyclooxygenase, lipoxygenase, and glucose oxidase [16].”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Nitric oxide synthases: regulation and function
Forstermann, U., & Sessa, W. C. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr304 · Cited by 4,409
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378 · cited 1×
“The Steno-2 Study demonstrated that the risk of microvascular complications and cardiovascular events was significantly reduced by an intensified, target-driven, multifactorial intervention involving a combination of focused behavior modification and medications aimed at concomitant cardiovascular risk factors than by…”
BackgroundZhou, B., Lu, Y., Hajifathalian, K., Bentham, J., Di Cesare, M., Danaei, G., Bixby, H., Cowan, M., Ali, M., Taddei, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00618-8 · Cited by 4,311
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Einarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0728-6 · Cited by 2,312 · cited 1×
“3% of all deaths in diabetic patients [2].”
BackgroundRoles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis
Förstermann, U., Xia, N., & Li, H. (2017) · Circulation Research · doi:10.1161/circresaha.116.309326 · Cited by 1,519 · cited 1×
“There is an interaction between endothelial function and oxidative stress [3,17].”
BackgroundMetabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035
Endothelial dysfunction and vascular disease - a 30th anniversary update
Vanhoutte, P. M., Shimokawa, H., Feletou, M., & Tang, E. H. C. (2017) · Acta Physiologica · doi:10.1111/apha.12646 · Cited by 937
McVeigh, G. E., Brennan, G. M., Johnston, G. D., McDermott, B. J., McGrath, L. T., Henry, W. R., Andrews, J. W., & Hayes, J. R. (1992) · Diabetologia · doi:10.1007/bf00429099 · Cited by 916 · cited 1×
“Clinical studies have shown that endothelial function assessed by endothelium-dependent vasodilation is impaired in diabetic patients [14,15].”
BackgroundDu, X. L., Edelstein, D., Dimmeler, S., Ju, Q., Sui, C., & Brownlee, M. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11235 · Cited by 907 · cited 1×
“For instance, eNOS activity is inhibited by O-acetylglucosaminylation of the eNOS protein at the Akt site [22], leading to decreased NO production and consequent endothelial dysfunction.”
BackgroundMattagajasingh, I., Kim, C.-S., Naqvi, A., Yamamori, T., Hoffman, T. A., Jung, S.-B., DeRicco, J., Kasuno, K., & Irani, K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704329104 · Cited by 881
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795
Zeng, G., Nystrom, F. H., Ravichandran, L. V., Cong, L.-N., Kirby, M., Mostowski, H., & Quon, M. J. (2000) · Circulation · doi:10.1161/01.cir.101.13.1539 · Cited by 745 · cited 1×
“eNOS is phosphorylated at Ser1177 by Akt, resulting in increased NO production [31,32].”
BackgroundZeng, G., & Quon, M. J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118871 · Cited by 726 · cited 1×
“eNOS is phosphorylated at Ser1177 by Akt, resulting in increased NO production [31,32].”
BackgroundNyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680
Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus
Mather, K. J., Verma, S., & Anderson, T. J. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01129-9 · Cited by 513
Fundamentals on the biochemistry of peroxynitrite and protein tyrosine nitration
Bartesaghi, S., & Radi, R. (2018) · Redox Biology · doi:10.1016/j.redox.2017.09.009 · Cited by 485
Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences
Gallo, L. A., Wright, E. M., & Vallon, V. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114561992 · Cited by 395 · cited 1×
“Sodium-glucose cotransporter 2 (SGLT2) inhibitors lower blood glucose levels by increasing glucose excretion into urine through inhibition of renal glucose reabsorption [67].”
BackgroundMetformin modulates hyperglycaemia‐induced endothelial senescence and apoptosis through SIRT1
Arunachalam, G., Samuel, S. M., Marei, I., Ding, H., & Triggle, C. R. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12496 · Cited by 221
Koska, J., Sands, M., Burciu, C., D’Souza, K. M., Raravikar, K., Liu, J., Truran, S., Franco, D. A., Schwartz, E. A., Schwenke, D. C., et al. (2015) · Diabetes · doi:10.2337/db14-0976 · Cited by 174 · cited 1×
“It has also been shown that eNOS activation in endothelial cells through GLP1-R and AMP-activated protein kinase (AMPK) activation is involved in the augmentation of endothelial function by GLP-1R agonists [53].”
BackgroundMetformin improves endothelial function in patients with metabolic syndrome
VITALE, C., MERCURO, G., CORNOLDI, A., FINI, M., VOLTERRANI, M., & ROSANO, G. M. C. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01531.x · Cited by 164
Can Metformin Exert as an Active Drug on Endothelial Dysfunction in Diabetic Subjects
Salvatore, T., Pafundi, P. C., Galiero, R., Rinaldi, L., Caturano, A., Vetrano, E., Aprea, C., Albanese, G., Di Martino, A., Ricozzi, C., et al. (2020) · Biomedicines · doi:10.3390/biomedicines9010003 · Cited by 97
Rodbard, H. W., Peters, A. L., Slee, A., Cao, A., Traina, S. B., & Alba, M. (2017) · Diabetes Care · doi:10.2337/dc16-1353 · Cited by 94 · cited 1×
“SGLT2 inhibitors have been shown to reduce postprandial glucose levels and decrease overall glucose variability in patients with diabetes mellitus [68,69].”
Background
Cited by
The role of oxidative stress in diabetes mellitus-induced vascular endothelial dysfunction
An, Y., Xu, B.-T., Wan, S.-R., Ma, X.-M., Long, Y., Xu, Y., & Jiang, Z.-Z. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01965-7 · Cited by 396
Yang, D.-R., Wang, M.-Y., Zhang, C.-L., & Wang, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1359255 · Cited by 280
Metadata
- Authors
- Maruhashi, T., & Higashi, Y.
- Venue
- Antioxidants
- Publisher
- MDPI AG
- Published
- 2021-08-18
- Volume
- 10
- Issue
- 8
- Pages
- 1306
- ISSN
- 2076-3921 (ISSN-L)
- OpenAlex
- W3196021061
- Cited by
- 185
- References
- 31
- FWCI
- 14.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.